Finding novel small molecule leads against difficult-to-drug targets was once a challenging task to achieve at scale. X-Chem’s CEO, Matt Clark, helped create DNA-encoded libraries (DELs) about 15 years ago to address this problem. DEL technology is revolutionizing drug discovery with the ability to screen billions of compounds with astonishing speed and efficiency.
In this webinar, Christopher Hupp, Ph.D., associate director of Discovery Chemistry at X-Chem, will present the history of the development of DELs to their current use in early drug discovery. He will show how they can benefit biopharmaceutical companies searching for the next major drug. Starting from the rise and subsequent fall of combinatorial chemistry, Dr. Hupp will explain how this, the foundational thought experiments of Brenner and Lerner, and advances in DNA sequencing technologies, set the stage for the development of the first DELs.
As a new technology, no particular lab, company or organization had significant experience with DELs, providing an opportunity for a motivated set of scientists to become the industry-leading experts in this paradigm-shifting platform.
Filling the gap, Dr. Hupp will explain how a group of scientist-founders created X-Chem to harness this new technology. X-Chem has been pioneering DNA-encoded library technology for over a decade and has innovated a superior approach to library design, honed their expertise in selection science and developed unique informatics tools to help drive drug discovery.
Dr. Hupp will present several case studies highlighting how the use of DEL technology has provided small molecule drug discovery solutions in the past. These concrete examples will illustrate how a deep understanding of the DEL platform will help in your drug discovery program.
Register for this webinar to find out how strong expertise with DEL libraries can empower you to screen hundreds of billions of compounds against your target with the ground-breaking power of DEL technology.
Christopher Hupp, Ph.D., Associate Director, Discovery Chemistry, X-Chem, Inc.
Christopher Hupp, Ph.D., joined X-Chem in September 2010 and now serves as the associate director of Discovery Chemistry. Dr. Hupp has over 10 years of experience in discovery chemistry and in the design, preparation and application of DNA-encoded libraries for early drug discovery. He received his B.A. in chemistry from Kalamazoo College, Ph.D. in organic chemistry from Michigan State University and postdoctoral training in medicinal chemistry at Harvard Medical School/McLean Hospital.Message Presenter
Who Should Attend?
- Medicinal chemists, biochemists and biologists
- Investigators looking for equity against a target
- Practitioners of hit identification and lead optimization
What You Will Learn
- Learn the capabilities and power of DNA-encoded libraries for early drug discovery
- See examples of a DEL platform utilized successfully
- Understand how DEL technology — when applied with expertise — can help your drug discovery program
X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. X-Chem empowers partners to rapidly screen billions of diverse, drug-like compounds simultaneously and easily identify potent hits that exhibit desired selectivity and mode of action with attractive physicochemical properties. In-house lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification. For more about X-Chem, visit x-chemrx.com.